Divi's Laboratories Limited vs Shukra Pharmaceuticals Limited
A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Shukra Pharmaceuticals Limited (SHUKRAPHAR) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Divi's Laboratories Limited leads DIVISLAB vs SHUKRAPHAR on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation40
- Profitability04
- Growth11
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
DIVISLAB takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
SHUKRAPHAR takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
- − ["Stock is trading at 14.39 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 29.9%", "Company is almost debt free.", "Company has delivered good sales growth of 38.8% CAGR over last 5 years"]
- − ["Stock is trading at 33.44 times its book value"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.